Back
![](https://s3.ap-southeast-1.amazonaws.com/buckets.epicareer.com/employer/logo/20240124093444-2278232-alnylam-pharmaceuticals.jpg)
Alnylam Pharmaceuticals
Founded by : Phillip Sharp & Paul Schimmel & David Bartel & Thomas Tuschl & and Phillip Zamore, 1 January 2002
Middlesex County, United States
More than 5000 employees
About the Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam has a number of RNAi-based drugs in development, including ONPATTRO, the first FDA-approved RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. The company's pipeline also includes potential treatments for diseases such as hemophilia, hypercholesterolemia, and porphyria. Alnylam is committed to advancing the field of RNAi therapeutics and has formed collaborations with numerous pharmaceutical companies and research institutions to further its mission.
Industry Type
According to the GICS (Global Industry Classification Standard) version of March 2023, Alnylam Pharmaceuticals’s industry classification falls within the following categories:
- Sector: Health Care
- Industry group: Pharmaceuticals, Biotechnology & Life Sciences
- Industry: Biotechnology
- Sub-Industry: Biotechnology
Videos and Photos
![](https://s3.ap-southeast-1.amazonaws.com/buckets.epicareer.com/employer/logo/20240607221016-yw7rgfse2yi6jmf4ex5o5m6fna.jpg.jpg)
Company Address
675 W Kendall St, Cambridge, MA 02142, USA
Source : Google maps